Your browser doesn't support javascript.
loading
COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss.
Crabb, Simon J; Martin, Karen; Abab, Julia; Ratcliffe, Ian; Thornton, Roger; Lineton, Ben; Ellis, Mary; Moody, Ronald; Stanton, Louise; Galanopoulou, Angeliki; Maishman, Tom; Geldart, Thomas; Bayne, Mike; Davies, Joe; Lamb, Carolynn; Popat, Sanjay; Joffe, Johnathan K; Nutting, Chris; Chester, John; Hartley, Andrew; Thomas, Gareth; Ottensmeier, Christian; Huddart, Robert; King, Emma.
Affiliation
  • Crabb SJ; Cancer Sciences Unit, University of Southampton, Southampton, United Kingdom.
  • Martin K; Southampton Clinical Trials Unit, University of Southampton, Southampton, United Kingdom.
  • Abab J; Southampton Clinical Trials Unit, University of Southampton, Southampton, United Kingdom.
  • Ratcliffe I; Southampton Clinical Trials Unit, University of Southampton, Southampton, United Kingdom.
  • Thornton R; NHS Research, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
  • Lineton B; Institute of Sound and Vibration Research, University of Southampton, Southampton, United Kingdom.
  • Ellis M; Southampton Clinical Trials Unit, University of Southampton, Southampton, United Kingdom.
  • Moody R; Patient and Public Involvement Representative, United Kingdom.
  • Stanton L; Southampton Clinical Trials Unit, University of Southampton, Southampton, United Kingdom.
  • Galanopoulou A; Southampton Clinical Trials Unit, University of Southampton, Southampton, United Kingdom.
  • Maishman T; Southampton Clinical Trials Unit, University of Southampton, Southampton, United Kingdom.
  • Geldart T; Royal Bournemouth and Christchurch NHS Foundation Trust, Bournemouth, United Kingdom.
  • Bayne M; Poole Hospital NHS Foundation Trust, Poole, United Kingdom.
  • Davies J; Poole Hospital NHS Foundation Trust, Poole, United Kingdom.
  • Lamb C; The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.
  • Popat S; Institute of Cancer Research and Royal Marsden Foundation Trust, London, United Kingdom.
  • Joffe JK; St James' University Hospital, Leeds, United Kingdom.
  • Nutting C; Institute of Cancer Research and Royal Marsden Foundation Trust, London, United Kingdom.
  • Chester J; College of Biomedical and Life Sciences, Cardiff University and Velindre Cancer Centre, Cardiff, United Kingdom.
  • Hartley A; Queen Elizabeth Hospital, Birmingham, United Kingdom.
  • Thomas G; Cancer Sciences Unit, University of Southampton, Southampton, United Kingdom.
  • Ottensmeier C; Cancer Sciences Unit, University of Southampton, Southampton, United Kingdom.
  • Huddart R; Institute of Cancer Research and Royal Marsden Foundation Trust, London, United Kingdom.
  • King E; Cancer Sciences Unit, University of Southampton, Southampton, United Kingdom; Poole Hospital NHS Foundation Trust, Poole, United Kingdom. Electronic address: E.King@soton.ac.uk.
Eur J Cancer ; 87: 75-83, 2017 12.
Article in En | MEDLINE | ID: mdl-29128692
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Aspirin / Cisplatin / Protective Agents / Hearing / Hearing Loss / Neoplasms / Antineoplastic Agents Type of study: Clinical_trials / Diagnostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: Eur J Cancer Year: 2017 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Aspirin / Cisplatin / Protective Agents / Hearing / Hearing Loss / Neoplasms / Antineoplastic Agents Type of study: Clinical_trials / Diagnostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: Eur J Cancer Year: 2017 Document type: Article Affiliation country: